In recent years, under the background of the continuous acceleration of China's pharmaceutical innovation and development, the "going to sea" of innovative drugs has become the
norm.
It is worth noting that at the same time, in order to seek new growth points, the pace of "going overseas" is also accelerating
.
The development of domestic pharmaceutical equipment to the high-end market will become a general trend (Image source: Pharmaceutical Network)
For example, over the years, while continuing to expand its product line and comprehensively layout in the fields of engineering, equipment and consumables, Dongfulong has been establishing overseas R&D and design centers, and is committed to becoming a world-class pharmaceutical overall solution provider
.
According to the data, the company's overseas revenue volume has achieved high year-on-year growth in 21 years, of which the revenue in Europe is 729 million yuan, a year-on-year increase of about 150%, and the revenue in Asia is 298 million yuan, a year-on-year increase of about 60%.
Overseas revenue accounted for 24.
5%, an increase of approximately 6.
8%
year-on-year.
It should be noted that after the internationalization of Dongfulong in 2003, the previous overseas income mainly came from the Asian region
.
However, in February 2022, after Dongfulong supplied liquid dispensing systems, filling systems, lamp inspection and back-end packaging equipment to the French factory of Recipharm, a large CDMO company, the industry believes that this means that the export place of Dongfulong products has begun to enter the supply chain of developed countries from overseas markets such as Russia and India, and the market will further expand
in the future.
In recent years, Chutian Technology has also accelerated its international strategic layout
through the acquisition of German Romaco.
In the first half of 2021, Romaco Group brought 700 million yuan of revenue
to Chutian Technology.
According to the survey content disclosed by Chutian Technology in July last year, in the next 3-5 years, Chutian also plans to maintain an annual increase of 10%-20% in export business, and by about 2025, the export business income of Chutian headquarters will account for 40%-50% of the total revenue, accounting for half of the total revenue
.
It is worth mentioning that in September last year, Canaan Technology also predicted that the next 3~5 years of orders are expected, the international market is an important part, from the perspective of the international market, with the continuous innovation of product technology, in the high-end market will usher in more product export opportunities
.
In addition, Shanghai Lu Xiangyi is meeting the needs of the domestic market, constantly innovating and developing new products, and striving to overcome difficulties in high-tech, while also accelerating the export of products to overseas markets
.
It is reported that in recent years, Shanghai Lu Xiangyi's centrifuge products in Canada, Chile, Thailand, Pakistan, the Philippines, Malaysia, Vietnam, South Africa, Europe and the United States and other countries have increased the order volume has been greatly improved, and its products have also won the favor and trust
of many customers at home and abroad with good quality.
Recently, another batch of centrifuges from Shanghai Lu Xiangyi has been exported to Russia, including the floor-standing high-speed refrigerated centrifuge of model H2500R, TGL-21M large-capacity high-speed refrigerated centrifuge, TG20.
5 tabletop high-speed large-capacity centrifuge, and TD5M multi-tube frame automatic balancing centrifuge
.
Industry analysts believe that in order to expand the market, many domestic pharmaceutical equipment companies are accelerating the internationalization strategy and opening up the growth ceiling
.
Affected by this, the overseas revenue of leading enterprises is expected to usher in a further increase
in the future.
However, it should be noted that at the same time, local pharmaceutical companies also need to accelerate exploration and breakthroughs
in product technology and innovation.
It is reported that compared with the foreign pharmaceutical machine industry, the domestic pharmaceutical equipment industry still presents a "small", "scattered" and "chaotic" market pattern, especially in the high-end pharmaceutical machine market, domestic enterprises still have a huge space to be tapped, so it is necessary to continue to increase investment in research and development, strengthen core technology research, to further enhance market competitiveness
.
It is understood that in fact, the development of pharmaceutical equipment to the high-end market has become the consensus
of all parties.
In September 2020, the National Development and Reform Commission and other four departments jointly issued the "Guiding Opinions on Expanding Investment in Strategic Emerging Industries to Cultivate and Expand the Growth Pole of New Growth Points", which proposed to focus on supporting the production of high-end equipment such as high-end medical equipment and pharmaceutical equipment, and implement pilot demonstrations
of intelligent manufacturing and intelligent construction.
In this context, the industry expects that the competition of domestic enterprises in the high-end pharmaceutical equipment market will continue to intensify
in the future.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
